Detalhe da pesquisa
1.
Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.
N Engl J Med;
376(8): 717-728, 2017 02 23.
Artigo
em Inglês
| MEDLINE
| ID: mdl-28225674
2.
Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial.
Ann Emerg Med;
65(2): 204-13, 2015 Feb.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25182544
3.
A phase 1 study investigating DX-2930 in healthy subjects.
Ann Allergy Asthma Immunol;
113(4): 460-6.e2, 2014 Oct.
Artigo
em Inglês
| MEDLINE
| ID: mdl-24980392
4.
Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study.
Neurology;
102(5): e209151, 2024 Mar 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38330285
5.
Natural killer T cells are not the predominant T cell in asthma and likely modulate, not cause, asthma.
J Allergy Clin Immunol;
125(5): 980-4, 2010 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20304475
6.
A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy.
Adv Ther;
38(6): 3203-3222, 2021 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33963971
7.
Characterization of anaphylaxis after ecallantide treatment of hereditary angioedema attacks.
J Allergy Clin Immunol Pract;
3(2): 206-212.e4, 2015.
Artigo
em Inglês
| MEDLINE
| ID: mdl-25609335
8.
System for simultaneous tissue-specific and disease-specific regulation of therapeutic gene expression.
Hum Gene Ther;
14(13): 1255-64, 2003 Sep 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12952597